Clinical Trial Update: Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial of SOM230 (pasireotide) in unresectable hepatocellular carcinoma has completed enrollment and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SOM230 (pasireotide)

Snippet

Sponsor: Lynn Feun | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-07-12